Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics company based in China, has entered into a strategic partnership with Quest Diagnostics, a top global provider of diagnostic information services. The collaboration aims to develop and offer blood-based clinical research services specifically tailored for Alzheimer’s disease (AD). Through this initiative, Dian Dx is committed to raising public awareness about predictive measures for AD and emphasizing the importance of early detection and diagnosis by encouraging participation in AD assessment testing programs.
In the realm of AD diagnosis, conventional detection methods such as amyloid positron emission tomography (PET) scans and cerebrospinal fluid tests present challenges due to their complexity, high costs, and invasive nature. To address these issues, Dian Dx will introduce the Quest AD Detect β-amyloid 42/40 blood detection method, which utilizes IP-LC-MS/MS technology. This innovative approach enables physicians to evaluate the ratio of two amyloid beta proteins in plasma, Aβ42/Aβ40, from a single blood sample. Monitoring the levels of Aβ over time can help assess the risk of AD progression. The blood test has been meticulously analyzed and validated to assist in the risk assessment of AD and to identify patients who might benefit from additional intervention strategies.- Flcube.com
